Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective

News provided by

Nov 04, 2013, 11:13 ET

NEW YORK, Nov. 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective
http://www.reportlinker.com/p01859474/Epigenetics-Emerging-Targets-Available-Technologies-Expert-Interviews-and-an-Epigenetic-Community-Perspective.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

This report covers several technologies, epigenetic targets, and market outlook. The first part of this report covers necessary background information, mostly pertaining to epigenetic targets, and the reasons they are being investigated. Several companies have kindly disclosed several strategies, methods, and techniques that they use for either target identification or technology development.

In Part I of the report, several targets and their properties are discussed including histone methyltransferases, histone demethylases, and bromodomains. A list of known histone modifications is also present. This includes companies (if applicable), targets being studied, diseases they are associated with, and their clinical developmental status. Part II details specific pharmaceutical/biopharmaceutical companies and their strategies behind their target identifications and validation. These companies include Constellation Pharmaceuticals, Epizyme Inc., and EpiTherapeutics. Part III of the report covers technologies and assays available from the following biotechnology companies: Active Motif (including ChIP technology and a current list of validated antibodies), Cayman Chemical, and Reaction Biology.

Areas covered for Parts I and II include:
• Company backgrounds
• Areas of interest
• Challenges encountered
• Competitive advantages
• Partnerships

Additionally, these sections also include interviews with CEOs, CSOs, and expert scientists of the participating companies.

The last section of the report, Part IV, gives insight into the epigenetics community. Insight Pharma Reports polled a survey which had more than 150 responses. Specific areas highlighted are targets under investigation, market outlook, and how partnerships with external organizations have advanced the industry.

Executive Summary

Part I: Epigenetic Background and Target Information

Chapter 1
• What is epigenetics?
• Histone modifications
- Histone methyltransferases
- Arginine methyltransferases (RMT)
- Histone demethylases
- Epigenetic readers

Part II: Targets in the Industry

Chapter 2
• Constellation Pharmaceuticals
• Company background
• Areas of research
- SWI/SNF
- EZH2
- DOT1L
- BET bromodomains
• Challenges encountered
• Competitive advantage
• Partnerships
• Future endeavors
• Interview with Robert Sims
- Company background
- Research objectives
- Benefits and challenges
- Future endeavors

Chapter 3
• EpiTherapeutics
• Company background
• Areas of research
- PLU1
- FBXL10
- GASC1
• Chemistry platform
• Challenges encountered
• Competitive advantage
• Partnerships and future endeavors
• Interview with Martin Bonde
- Company background
- Areas of research
- Chemistry platform
- Challenges encountered
- Competitive advantage
- Partnerships
- Future endeavors

Chapter 4
• Epizyme Inc.
• Company background
• Areas of research
- DOT1L
- EZH2
• Challenges encountered
• Competitive advantage
• Partnerships
• Future endeavors
• Interview with Jesse Smith
- Background
- Areas of research
- Target validation
- Use of biomarkers
- Challenges encountered
- Partnerships
- Future endeavors

Part III: Rising Technologies and Company Strategies

Chapter 5
• Active Motif
• Company background
• Chromatin Immunoprecipitation (ChIP) technology
• Competitive advantage
• Challenges encountered
• Validating antibodies using ChIP, ChIP-chip, and ChIP-Seq
• Partnerships and strategies
• Future endeavors
• Interview with Kyle Hondorp
- Company background
- Immunoprecipitation technology
- Challenges encountered
- Future endeavors
- Partnerships and growth

Chapter 6
• Cayman Chemical
• Company background
• Applications
- Time-resolved fluorescence resonance energy transfer (TR-FRET) assays
- S-adenosyl-L-methionine (SAM)-screener assays
• Challenges encountered
• Partnerships
• Future outlook
• Interview with Dr. Levi Blazer
- Company background
- Partnerships
- Areas of research
- Assays
- Challenges encountered
- Future endeavors

Chapter 7
• Reaction Biology Corporation
• Company background
• Reaction Biology Corporation's role in epigenetics
• Competitive strategies
• Future outlook
• Interview with Haiching Ma
- Company background
- Areas of research
- Partnerships
- Future expectations

Part IV: Epigenetics in the Community

Chapter 8
• Survey results
• Areas of study
• Market outlook
• Partnerships

References

About Cambridge Healthtech Institute

Tables

Table 1.1 List of known histone modifications in vertebrates
Table 1.2: Targets and their developmental status
Table 5.1: Validated antibodies using ChIP, ChIP-chip, and ChIP-Seq assays

Figures

Figure 1.1: Interest in epigenetic targets over time
Figure 5.1: ChIP-chip validation steps
Figure 5.2: ChIP antibody validation steps
Figure 8.1: Survey participants
Figure 8.2: Popular areas of study
Figure 8.3: Technology of choice
Figure 8.4: Targets of interest
Figure 8.5: Expected diseases to benefit from therapeutic applications
Figure 8.6: Classes expected to receive FDA approval
Figure 8.7: Participants in partnerships
Figure 8.8: Impact of partnerships on research

To order this report: Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective
http://www.reportlinker.com/p01859474/Epigenetics-Emerging-Targets-Available-Technologies-Expert-Interviews-and-an-Epigenetic-Community-Perspective.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical